Methazolamide

Methazolamide

SCHEMBL24686

CC(=O)/N=c1\sc(S(N)(=O)=O)nn1C

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

CA1CA2CA4CA7

The experimentally established mechanism targets of Methazolamide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CA1 known ✓ P00915 20/20 1.00
CA2 known ✓ P00918 20/20 1.00
CA4 known ✓ P22748 3/20 1.00
CA7 known ✓ P43166 3/20 1.00
CA9 Q16790 7/20 1.00
CA12 O43570 3/20 1.00
CA3 P07451 3/20 1.00
CA6 P23280 3/20 1.00
CA5A P35218 3/20 1.00
CA13 Q8N1Q1 3/20 1.00
CA14 Q9ULX7 3/20 1.00
CA5B Q9Y2D0 3/20 1.00
MAPT P10636 1/20 1.00
CYP2C9 P11712 1/20 1.00
HPGD P15428 1/20 1.00
HTT P42858 1/20 1.00
HSD17B10 Q99714 1/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Methazolamide SCHEMBL9312473 1.00 CA1 (1.00) CA1CA2CA9CA12CA3
Methazolamide SCHEMBL13825893 1.00 CA1 (1.00) CA1CA2CA9CA12CA3
Methazolamide SCHEMBL24687 1.00 CA1 (1.00) CA1CA2CA9CA12CA3
Methazolamide SCHEMBL11042633 0.98 CA1 (0.97) CA1CA2CA9CA12CA3
Methazolamide SCHEMBL11042630 0.98 CA1 (0.97) CA1CA2CA9CA12CA3
Methazolamide SCHEMBL7037043 0.98 CA1 (0.97) CA1CA2CA9CA12CA3
Methazolamide SCHEMBL7037047 0.98 CA1 (0.97) CA1CA2CA9CA12CA3
Methazolamide SCHEMBL28556858 0.97 CA1 (0.94) CA1CA2CA9CA12CA3
Methazolamide SCHEMBL29142823 0.92 CA1 (0.84) CA1CA2CA9CA12CA3
Methazolamide SCHEMBL6258297 0.89 CA1 (0.80) CA1CA2CA9CA12CA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 12395 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12630599-B2 CA2 compositions and methods for tunable regulation OBSIDIAN THERAPEUTICS, INC. (US) 2026-05-19 US claimed
EP-4739302-A2 HYALURONIC ACID BASED DRUG DELIVERY SYSTEMS Cella Therapeutics, LLC (US) 2026-05-13 EP claimed
EP-4724839-A2 CONTACT LENSES INCLUDING MEDICAMENTS AND METHODS OF MAKING AND USING SAME INCLUDING SLOW RELEASE OF GLAUCOMA TREATING DRUGS AND COMFORT ENHANCING DRUGS Mediprint Ophthalmics Inc. (US) 2026-04-15 EP claimed
EP-4724079-A2 METHODS AND COMPOSITIONS FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION Stealth BioTherapeutics Inc. (US) 2026-04-15 EP claimed
EP-4722714-A1 SIMULTANEOUS ANALYSIS OF FOOD-BORNE DOPING SUBSTANCES USING LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY (VFD: VACCINE FOR FOODBORNE DOPING) Korea Institute of Science and Technology (KR) 2026-04-08 EP claimed
US-20260090984-A1 CONTACT LENSES INCLUDING MEDICAMENTS AND METHODS OF MAKING AND USING SAME INCLUDING SLOW RELEASE OF GLAUCOMA TREATING DRUGS AND COMFORT ENHANCING DRUGS MEDIPRINT OPHTHALMICS INC. (US) 2026-04-02 US claimed
US-20260083709-A1 COMBINATION PHARMACOLOGICAL INTERVENTIONS FOR MULTIPLE MECHANISMS OF OBSTRUCTIVE SLEEP APNEA APNIMED INC DELAWARE (US) 2026-03-26 US claimed
US-20260048096-A1 METHODS AND COMPOSITIONS FOR PRESERVING THE RETINAL OUTER NUCLEAR LAYER (ONL), PHOTORECEPTORS, AND RETINAL THICKNESS STEALTH BIOTHERAPEUTICS INC. (US) 2026-02-19 US claimed
US-12551527-B2 Drug delivery systems for treatment of infections WAYNE STATE UNIVERSITY (US) 2026-02-17 US claimed
EP-4691568-A2 LOW-DOSE BRIMONIDINE COMBINATIONS AND USES THEREOF Eye Therapies, LLC (US) 2026-02-11 EP claimed
EP-0014642-B1 OPHTHALMIC COMPOSITIONS COMPRISING COMBINATIONS OF CARBONIC ANHYDRASE INHIBITORS AND S-(-)-1-(TERT-BUTYLAMINO)-3-(4-MORPHOLINO-1,2,5-THIADIAZOL-3-YL)-OXY-2-PROPANOL FOR TOPICAL APPLICATION IN THE TREATMENT OF ELEVATED INTRAOCULAR PRESSURE MERCK & CO. INC. (US) 1984-03-21 EP claimed
US-4438123-A Ophthalmic compositions of carbonic anhydrase inhibitors for topical application in the treatment of elevated intraocular pressure MERCK & CO., INC. (US) 1984-03-20 US claimed
EP-0083779-A1 Hyperuretic agents Beyer, Karl H., Jr. (US) 1983-07-20 EP claimed
EP-0036351-A2 Ophthalmic compositions of carbonic anhydrase inhibitors for topical application in the treatment of elevated intraocular pressure MERCK & CO. INC. (US) 1981-09-23 EP claimed
EP-0033042-A1 Ophthalmic inserts for lowering intraocular pressure comprising carbonic anhydrase inhibitors MERCK & CO. INC. (US) 1981-08-05 EP claimed
US-4221783-A A SULFONAMIDE, POTASSIUM OR SODIUM BICARBONATE AND CITRATE, MAGNESIUM CARBONATE OR OXIDE CENTRALA INDUSTRIALA DE MEDICAMENTE COSMETICE COLORANTI SI LACURI (RO) 1980-09-09 US claimed
EP-0014642-A2 Ophthalmic compositions comprising combinations of carbonic anhydrase inhibitors and S-(-)-1-(tert-butylamino)-3-(4-morpholino-1,2,5-thiadiazol-3-yl)-oxy-2-propanol for topical application in the treatment of elevated intraocular pressure MERCK & CO. INC. (US) 1980-08-20 EP claimed
US-4014334-A Laminated osmotic system for dispensing beneficial agent ALZA CORPORATION (US) 1977-03-29 US claimed
US-4008719-A Osmotic system having laminar arrangement for programming delivery of active agent ALZA CORPORATION (US) 1977-02-22 US claimed
US-3977404-A OSMOTIC DEVICE HAVING MICROPOROUS RESERVOIR ALZA CORPORATION (US) 1976-08-31 US claimed